Hui Lin, Principal Investigator

Contact Information

Email：huilin@bjmu.edu.cn

Research Interests

1）Exploration and mechanistic analysis of novel GPCR targets in metabolic diseases.

2）Pharmacologic modulation of GPCRs for osteoporosis and other bone-metabolic conditions.

3）Target discovery and therapeutic validation of GPCRs driving periodontitis.

Brief Research Interests: Membrane receptors and the regulatory mechanisms of bone and metabolic diseases.

Biography

Dr. Hui Lin's research is dedicated to the discovery of G protein-coupled receptor (GPCR) targets and the investigation of their regulatory mechanisms in skeletal and metabolic diseases. She has identified several key membrane receptors for steroid hormones and endogenous metabolic molecules, elucidating their regulatory roles in metabolic diseases and bone development. Based on these findings, she has developed various targeted intervention strategies. In the past five years, as first author (including co-first) or corresponding author (including co-corresponding), she has published numerous papers in high-impact international journals such as Science (2025), Nature (2022, 2025), Cell Metabolism (2024), Nature Chemical Biology (2022, 2025), PNAS (2022), and Signal Transduction and Targeted Therapy (2025). Three of these publications received dedicated commentaries. She was selected for the China Postdoctoral Innovative Talent Support Program ("BX Program"). Dr. Lin holds 3 invention patents and has presided over projects including the National Natural Science Foundation of China (NSFC) for Young Scientists.

Education and Professional Experience

2025.07 - Present: Peking University, School of Basic Medical Sciences, Department of Biophysics, Principal Investigator, Doctoral Supervisor

2022.09 - 2025.05: Shandong University, Oral Basic Medicine, Postdoctoral Researcher (Mentor: Prof. Shaohua Ge)

2017.09 - 2022.09: Shandong University, Physiology, Ph.D. (Supervisor: Prof. Xiao Yu)

2013.09 - 2017.06: China Pharmaceutical University, Pharmaceutics, B.S.

Publications

1. Lin H#, Ma C#, Cai K#, Guo L#, Wang X#, Lv L#, Zhang C#, Lin J#, Zhang D, Ye C, Wang T, Huang S, Han J, Zhang Z, Gao J, Zhang M, Pu Z, Li F, Guo Y, Zhou X, Qin C, Yi F, Yu X*, Kong W*, Jiang C*, Sun JP*. Metabolic signaling of ceramides through the FPR2 receptor inhibits adipocyte thermogenesis. Science. 2025 May;388(6746):eado4188. doi: 10.1126/science.ado4188. (Q1; IF: 45.8)

2. Zhang S#, Lin H#, Wang J#, Rui J#, Wang T#, Cai Z#, Huang S#, Gao Y, Ma T, Fan R, Dai R, Li Z, Jia Y, Chen Q, He H, Tan J, Zhu S, Gu R, Dong Z, Li M, Xie E, Fu Y, Zheng J*, Jiang C*, Sun J*, Kong W*. Sensing ceramides by CYSLTR2 and P2RY6 to aggravate atherosclerosis. Nature. 2025 May;641(8062):476-485. doi: 10.1038/s41586-025-08792-8. (Q1; IF: 48.5)

3. Zheng Y#, Jiang D#, Lu Y#, Zhang C#, Huang SM#, Lin H#, Zhang D#, Guo S#, Han J, Chen J, He Y, Zhang M, Gao Y, Guo Y, Wei R, Xia M, Qin Y, Liu Z, Yang F, Ge S, Yi F, Yu X*, Lin H*, Xiao P*, Sun JP*, Feng S*. Development of an allosteric adhesion GPCR nanobody with therapeutic potential. Nat Chem Biol. 2025 May 15. doi: 10.1038/s41589-025-01896-2. (Q1; IF: 13.7)

4. Lin H#, Ma C#, Zhuang X#, Liu S#, Liu D#, Zhang M#, Lu Y, Zhou G, Zhang C, Wang T, Zhang Z, Lv L, Zhang D, Ruan XZ, Xu Y*, Chai R*, Yu X*, Sun JP*, Chu B*. Sensing steroid hormone 17α-hydroxypregnenolone by GPR56 enables protection from ferroptosis-induced liver injury. Cell Metab. 2024 Nov 5;36(11):2402-2418.e10. doi: 10.1016/j.cmet.2024.09.007. (Q1; IF: 30.9)

5. Lin H#, Xiao P#, Bu RQ#, Guo S#, Yang Z#, Yuan D#, Zhu ZL, Zhang CX, He QT, Zhang C, Ping YQ, Zhao RJ, Ma CS, Liu CH, Zhang XN, Jiang D, Huang S, Xi YT, Zhang DL, Xue CY, Yang BS, Li JY, Lin HC, Zeng XH, Zhao H, Xu WM, Yi F*, Liu Z*, Sun JP*, Yu X*. Structures of the ADGRG2-Gs complex in apo and ligand-bound forms. Nat Chem Biol. 2022 Nov;18(11):1196-1203. doi: 10.1038/s41589-022-01084-6. (Q1; IF: 13.7)

6. Xiao P#, Guo S#, Wen X#, He QT#, Lin H#, Huang SM#, Gou L#, Zhang C, Yang Z, Zhong YN, Yang CC, Li Y, Gong Z, Tao XN, Yang ZS, Lu Y, Li SL, He JY, Wang C, Zhang L*, Kong L*, Sun JP*, Yu X*. Tethered peptide activation mechanism of the adhesion GPCRs ADGRG2 and ADGRG4. Nature. 2022 Apr;604(7907):771-778. doi: 10.1038/s41586-022-04590-8. (Q1; IF: 48.5)

7. An W#, Lin H#, Ma L#, Zhang C, Zheng Y, Cheng Q, Ma C, Wu X, Zhang Z, Zhong Y, Wang M, He D, Yang Z, Du L, Feng S, Wang C, Yang F, Xiao P*, Zhang P*, Yu X*, Sun JP*. Progesterone activates GPR126 to promote breast cancer development via the Gi pathway. Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2117004119. doi: 10.1073/pnas.2117004119. (Q1; IF: 9.1)

8. Lehmann J#*, Lin H#, Zhang Z#, Wiermann M, Ricken AM, Brinkmann F, Brendler J, Ullmann C, Bayer L, Berndt S, Penk A, Winkler N, Hirsch FW, Fuhs T, Käs J, Xiao P, Schöneberg T, Rauner M, Sun JP*, Liebscher I*. The mechanosensitive adhesion G protein-coupled receptor 133 (GPR133/ADGRD1) enhances bone formation. Signal Transduct Target Ther. 2025 Jun 30;10(1):199. doi: 10.1038/s41392-025-02291-y. (Q1; IF: 52.7)